Table 2.
Clinical and MRI demographics of the MPRAGE cohort.
| Characteristic | Long‐T1 PRL categorization | Center | ||||
|---|---|---|---|---|---|---|
| 0 long‐T1 PRL | ≥1 long‐T1 PRL | P/P FDR b | Brussels | Lausanne | P/P FDR b | |
| N = 106 a | N = 61 a | N = 113 a | N = 54 a | |||
| Age | 45.77 (12.19) | 44.37 (12.69) | 0.4/0.5 | 43.83 (12.87) | 48.24 (10.72) | 0.031/0.044 |
| Sex | ||||||
| Male | 35/106 (33%) | 26/61 (43%) | 0.2/0.2 | 41/113 (36%) | 20/54 (37%) | >0.9 |
| Female | 71/106 (67%) | 35/61 (57%) | 72/113 (64%) | 34/54 (63%) | ||
| Phenotype | ||||||
| RRMS | 81/106 (76%) | 34/61 (56%) | 0.005/0.008 | 80/113 (71%) | 35/54 (65%) | 0.4/0.5 |
| PMS | 25/106 (24%) | 27/61 (44%) | 33/113 (29%) | 19/54 (35%) | ||
| Disease duration | 10.09 (9.55) | 8.67 (9.18) | 0.3/0.4 | 8.99 (9.57) | 10.80 (9.04) | 0.058/0.078 |
| Treatment at baseline | ||||||
| Untreated | 46/103 (45%) | 27/59 (46%) | >0.9 | 61/113 (54%) | 12/49 (24%) | 0.004/0.006 |
| Platform | 8/103 (7.8%) | 4/59 (6.8%) | 8/113 (7.1%) | 4/49 (8.2%) | ||
| High efficacy | 34/103 (33%) | 18/59 (31%) | 29/113 (26%) | 23/49 (47%) | ||
| Very high efficacy | 15/103 (15%) | 10/59 (17%) | 15/113 (13%) | 10/49 (20%) | ||
| EDSS | 2.63 (1.95) | 3.70 (2.28) | 0.007/0.01 | 2.88 (2.07) | 3.31 (2.26) | 0.5 /0.5 |
| MSSS | 4.14 (2.52) | 5.77 (2.56) | <0.001 | 4.64 (2.58) | 4.92 (2.80) | 0.7/0.8 |
Bold P‐values indicate statistical significance (P < 0.05). Treatments: platform = injectable platform drugs; high efficacy = teriflunomide, dimethyl fumarate, fingolimod, siponimod, and ozanimod; very high efficacy = ocrelizumab, ofatumumab, rituximab, natalizumab, and cyclophosphamide. CP, choroid plexus; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; MSSS, Multiple Sclerosis Severity Score; lT1‐PRL, long‐T1 paramagnetic rim lesion; PMS, primary or secondary progressive MS; PRL, paramagnetic rim lesion; RRMS, relapsing–remitting MS normalized volumes, total structure volume/intracranial volume.
Mean (SD); n/N (%).
Wilcoxon rank sum test; Pearson's chi‐squared test; Fisher's exact test.